overall 1-year mortality was 3.2%, the 1-year myocardial infarction rate was 7.2%, and the l-year coronary artery bypass surgery rate was 13.2%. In the 78% of the cohort with all lesions successfully dilated and without major procedural complications (successful patients), the corresponding rates were 1.9%o, 2.6%, and 6.4%. Nearly 20% of all deaths, 40% of all infarctions, and 25% of all bypass operations occurred in the small subset of patients (6.8%) who sustained periprocedural occlusion. Event rates were higher in patients with multivessel disease than in those with one-vessel disease. At 1 year, angina-free status was reported by approximately three fourths of all surviving patients, regardless of initial success. However, compared with successful patients, unsuccessful patients underwent intervening bypass surgery (42% vs. 6%) to achieve asymptomatic status more frequently. Comparison of the 1-year event rates in the 1985-1986 registry with those in the 1977-1981 registry indicated reductions in all major untoward events. These reductions became apparent after controlling for the more extensive disease of the 1985-1986 registry patients. In contrast, use of repeat angioplasty has increased by 50%. We conclude that the improved initial results reported in the 1985-1986 registry cohort were maintained at 1-year follow-up. (Circulation 1989;80;421-428) T he National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty (PTCA) Registry provided baseline and follow-up information on patients undergoing this procedure in 1977in -1981 in . In 1985 of the initial registry sites initiated a new registry to eval-
uate the results of current techniques of angioplasty in 2,000 patients. Baseline results from the new registry showed that despite the higher risk status of the patients, in-hospital outcome was more favorable with improved angiographic success and decreased emergency and elective bypass surgery See p 700 rates compared with the earlier cohort.1 This report describes 1-year mortality, morbidity, angina, repeat revascularization, and self-assessed life-style status for the new registry patients. Comparison is made with the results obtained in the early registry cohort.
Methods
Eligibility criteria for the registry and the patient population have been previously described.*' The registry recruitment goal of 2,000 patients was achieved in 9 months, between August 1985 and May 1986.
The 1,801 of 2,096 consecutive patients who had angioplasty for the first time and did not have it in the setting of an acute myocardial infarction constitute the 1985-1986 "new registry."*41 Of these patients, 1,762 (98%) were either contacted at 1 year or died before 1-year follow-up. Of the remaining 39 patients (2%) who could not be contacted at 1 year, 15 are now known to be alive, eight others reside outside of North America, 10 refused to be followed, and six have yet to be located. Average time from first angioplasty to first anniversary contact was approximately 1.2 years.
Between 1977 and September 1981, the same 15 registry centers had entered 1,130 consecutive angioplasty cases (again, outside the setting of acute myocardial infarction) who became participants in long-term follow-up. These patients are referred to as the "old registry" follow-up cohort.
Definitions
Vessel disease was classified as one-vessel or multiple-vessel according to the definitions of the Coronary Artery Surgery Study.2 Patients with 50% or more stenosis of the left main coronary artery were classified as having multiple-vessel disease. In-hospital angiographic success was defined as a reduction of stenosis by at least 20% in all lesions in which angioplasty was attempted. In-hospital clinical success was defined as angiographic success without in-hospital death, myocardial infarction, or coronary artery bypass graft surgery. An occlusion was defined as abrupt closure of a dilated lesion or adjacent segment, either in or outside of the catheterization laboratory. Abrupt closure outside of the laboratory was detected when patients became symptomatic and subsequently underwent recatheterization. In a few instances, the investigators indicated abrupt closure in association with myocardial infarction or emergency bypass surgery without direct angiographic documentation of the closure.
All myocardial infarctions after angioplasty were counted as events, whether they occurred spontaneously or in association with angioplasty or coronary artery bypass graft surgery procedures. All infarctions were documented by at least two of the following: clinical symptoms, electrocardiographic evidence (Q wave criteria of a definite myocardial infarction according to the Minnesota Code3), and enzyme changes (more than double upper normal limits of creatinine kinase and/or presence of creatinine kinase MB). Infarctions after initial hospitalization were observed only if they required hospitalization. Coronary-artery bypass graft surgery after angioplasty was also considered to be an untoward event.
Repeat angioplasty was defined as an angioplasty procedure that was performed after the patient was discharged from the hospital after initial angioplasty.
Patients were considered to have angina at 1 year if during a structured follow-up interview, they reported its occurrence within the month previous to contact. Patients were classified as being on maintenance drug therapy when they reported taking /3-blockers, calcium blockers, or long-acting nitrates on a regular daily basis at the time of follow-up. The indications for and the choices of medications were left to the discretion of the referring physicians. Therapy at 1 5 .7% of patients (3.5% had emergency bypass surgery and 2.2% elective bypass surgery), and 7.6% of patients had bypass surgery during follow-up. In-hospital, follow-up, and combined 1-year mortality, infarction, and bypass surgery rates were all higher for patients with multivessel disease than for those with one-vessel disease.
Repeat angioplasty was performed in about 18% of both one-and multivessel-disease subgroups. Of the 333 patients who had repeat angioplasty procedures, 86% had only one after initial angioplasty, 12% had two, and 2% had three or four repeat procedures. were also more prevalent in patients with multivessel disease. For mortality, the confidence interval for the adjusted risk estimate includes unity. The higher risk for myocardial infarction and coronary artery bypass graft surgery remains significant after adjustment.
One-year event rates in the subgroup of 1,409 clinically successful patients are displayed in Table  3 . By definition, these patients had no in-hospital events.
In-hospital and follow-up events were also examined by occurrence of abrupt occlusion associated with first angioplasty (Table 4) . Occlusion as a complication of angioplasty occurred either in the catheterization laboratory or during postangioplasty hospitalization in 122 patients (6.8%). The occlusion rate was 6.0% in patients with one-vessel disease and 7.5% in patients with multivessel disease. The risk of mortality, both in-hospital and *n may be less than the sum of the ns of the first two columns if the same patient had an event both in-hospital and during follow-up. 
Discussion
The NHLBI PTCA Registry previously reported that despite the broader application of coronary angioplasty, the initial success rate was increased without an increased risk of immediate complications.' Our present follow-up data from the same cohort also indicate a sustained clinical benefit at 1 year after the procedure.
Cumulative mortality, myocardial infarction, and bypass surgery rates at 1-year follow-up in the 1985-1986 registry were 3.2%, 7.2%, and 13.2%, respectively, for all patients and 1.9%, 2.6%, and 6.4%, respectively, for initially successful patients. Though all major event rates in-hospital and during follow-up were higher in patients who had multivessel disease, other risk factors associated with multivessel disease also contributed to the elevated CABG, coronary artery bypass graft surgery; CHC, Canadian Heart Class.
*Regular daily use of (3-blockers, calcium blockers, and/or long-acting nitrates. 
